Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

155 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Rationale and Design of the STOP-OB Study for Evaluating the Effects of Tofogliflozin and Glimepiride on Fat Deposition in Type 2 Diabetes Patients Treated with Metformin/DPP-4 Inhibitor Dual Therapy.
Ishihara H, Anai M, Seino H, Kitazawa T, Ohashi H, Ai M, Inoue M, Fujishiro M, Inazawa T, Kuroda H, Yamada M. Ishihara H, et al. Among authors: anai m. Diabetes Ther. 2018 Oct;9(5):2117-2125. doi: 10.1007/s13300-018-0491-4. Epub 2018 Aug 25. Diabetes Ther. 2018. PMID: 30145651 Free PMC article.
Comparison of tofogliflozin versus glimepiride as the third oral agent added to metformin plus a dipeptidyl peptidase-4 inhibitor in Japanese patients with type 2 diabetes: A randomized, 24-week, open-label, controlled trial (STOP-OB).
Kitazawa T, Seino H, Ohashi H, Inazawa T, Inoue M, Ai M, Fujishiro M, Kuroda H, Yamada M, Anai M, Ishihara H. Kitazawa T, et al. Among authors: anai m. Diabetes Obes Metab. 2020 Sep;22(9):1659-1663. doi: 10.1111/dom.14059. Epub 2020 May 7. Diabetes Obes Metab. 2020. PMID: 32314464 Free PMC article. Clinical Trial.
Humoral regulation of resistin expression in 3T3-L1 and mouse adipose cells.
Shojima N, Sakoda H, Ogihara T, Fujishiro M, Katagiri H, Anai M, Onishi Y, Ono H, Inukai K, Abe M, Fukushima Y, Kikuchi M, Oka Y, Asano T. Shojima N, et al. Among authors: anai m. Diabetes. 2002 Jun;51(6):1737-44. doi: 10.2337/diabetes.51.6.1737. Diabetes. 2002. PMID: 12031960
Insulin resistance with enhanced insulin signaling in high-salt diet-fed rats.
Ogihara T, Asano T, Ando K, Chiba Y, Sekine N, Sakoda H, Anai M, Onishi Y, Fujishiro M, Ono H, Shojima N, Inukai K, Fukushima Y, Kikuchi M, Fujita T. Ogihara T, et al. Among authors: anai m. Diabetes. 2001 Mar;50(3):573-83. doi: 10.2337/diabetes.50.3.573. Diabetes. 2001. PMID: 11246877
Regulation of gut-derived resistin-like molecule beta expression by nutrients.
Fujio J, Kushiyama A, Sakoda H, Fujishiro M, Ogihara T, Fukushima Y, Anai M, Horike N, Kamata H, Uchijima Y, Kurihara H, Asano T. Fujio J, et al. Among authors: anai m. Diabetes Res Clin Pract. 2008 Jan;79(1):2-10. doi: 10.1016/j.diabres.2007.04.015. Epub 2007 Oct 23. Diabetes Res Clin Pract. 2008. PMID: 17936398
Hepatic Akt activation induces marked hypoglycemia, hepatomegaly, and hypertriglyceridemia with sterol regulatory element binding protein involvement.
Ono H, Shimano H, Katagiri H, Yahagi N, Sakoda H, Onishi Y, Anai M, Ogihara T, Fujishiro M, Viana AY, Fukushima Y, Abe M, Shojima N, Kikuchi M, Yamada N, Oka Y, Asano T. Ono H, et al. Among authors: anai m. Diabetes. 2003 Dec;52(12):2905-13. doi: 10.2337/diabetes.52.12.2905. Diabetes. 2003. PMID: 14633850
Resistin-like molecule beta activates MAPKs, suppresses insulin signaling in hepatocytes, and induces diabetes, hyperlipidemia, and fatty liver in transgenic mice on a high fat diet.
Kushiyama A, Shojima N, Ogihara T, Inukai K, Sakoda H, Fujishiro M, Fukushima Y, Anai M, Ono H, Horike N, Viana AY, Uchijima Y, Nishiyama K, Shimosawa T, Fujita T, Katagiri H, Oka Y, Kurihara H, Asano T. Kushiyama A, et al. Among authors: anai m. J Biol Chem. 2005 Dec 23;280(51):42016-25. doi: 10.1074/jbc.M503065200. Epub 2005 Oct 21. J Biol Chem. 2005. PMID: 16243841 Free article.
155 results